Next Article in Journal
Ethyl Caffeate Can Inhibit Aryl Hydrocarbon Receptor (AhR) Signaling and AhR-Mediated Potentiation of Mast Cell Activation
Next Article in Special Issue
Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key
Previous Article in Journal
VAX014, an Oncolytic Therapy, Reduces Adenomas and Modifies Colon Microenvironment in Mouse Model of CRC
Previous Article in Special Issue
MCD Diet Modulates HuR and Oxidative Stress-Related HuR Targets in Rats
 
 
Review
Peer-Review Record

Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models

Int. J. Mol. Sci. 2023, 24(12), 9996; https://doi.org/10.3390/ijms24129996
by Amina Basha 1,†, Sarah C. May 1,†, Ryan M. Anderson 1, Niharika Samala 2 and Raghavendra G. Mirmira 1,*
Reviewer 1: Anonymous
Reviewer 2:
Int. J. Mol. Sci. 2023, 24(12), 9996; https://doi.org/10.3390/ijms24129996
Submission received: 17 May 2023 / Revised: 6 June 2023 / Accepted: 9 June 2023 / Published: 10 June 2023

Round 1

Reviewer 1 Report

review article "Non-Alcoholic Fatty Liver Disease: Translating Disease  Mechanisms into Therapeutics Using Animal Models" is rather important in the sense that NAFLD is really big problem affecting people of all ages and ethnicities, still little is known to cure or treat it. Animal models can serve important gap in research in this area to understand the diseases and treatment discovery. I suggest authors to include in detail, viral hepatitis topic also in this paper to make it more useful and comprehensive. Because this is now important, as around 4 million people around the world suffer from this condition and I believe review articles are important for giving new directions for research. Also, authors are encouraged to include future directions in this research area. 

minor changes are required

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

Excellent review, gives all the tools for people in this arena to select the right model for their needs. Very well written.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 3 Report

Non-Alcoholic fatty liver disease (NAFLD) is characterized by an excess fat accumulation

in the liver. No current pharmacological treatment exist to manage NAFLD. This review

discuss different cellular and molecular mechanisms to contribute to NAFLD to develop

therapies.

It needs some major revisions:

1.-Line 32: fibrosis and non alcoholic steatohepatitis (NASH) are not the same. Please,

explain both disease to clarify the difference between them.

2.-In Table 1 appear steatosis but in the introduction is not well explain it, so I

recommend explaining: hepatic steatosis, fibrosis and NASH, in the section of

introduction.

3.-Line 37: Metabolic syndrome (MetS), please, add the abbreviation.

4.-Line 44: Please add the meaning of FDA

5.-Line 123: Add a reference to known where you found the definition of SREBPs.

6.-In section 5.1., lifestyle modifications, add as a lifestyle the adherence to the

Mediterranean diet. For example, the information of this article: doi:

10.3390/antiox11081440.

Comments for author File: Comments.pdf

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Round 2

Reviewer 1 Report

revised manuscript is improved 

Reviewer 3 Report

 Accept in present form

Back to TopTop